Actavis Initiated at Overweight at JPMorgan; Shares up 2%

Actavis (ACT) shares were initiated at an overweight at JPMorgan Chase & Co., which set a price target of $300.

ACT was up 2% at $221.20, trading with a 52-week range of $118.92 to $230.77.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution.


Elizabeth Clark, CPA, is a senior analyst for The Downtown Leader. If you have a great story idea for Elizabeth Clark, you can write at [ ].